Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy.

被引：0
|
作者：
Nastoupil, Loretta J.
Kamdar, Manali K.
Chavez, Julio C.
Ghesquieres, Herve
Ghosh, Monalisa
Holmes, Houston
Guillermo, Armando Lopez
Martinez-Lopez, Joaquin
Novak, Urban
Ribrag, Vincent
Roddie, Claire
机构：
[1] Univ Texas MD Anderson Canc Ctr Houston, Houston, TX USA
[2] Univ Colorado, Canc Ctr, Aurora, CO USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Hop Lyon Sud, Lyon, France
[5] Univ Michigan Hlth Syst, Ann Arbor, MI USA
[6] Texas Oncol Baylor Charles Sammons Canc Ctr, Dallas, TX USA
[7] Hosp Clin Barcelona, Barcelona, Spain
[8] Hosp 12 Octubre, Madrid, Spain
[9] Univ Hosp Bern, Med Oncol, Inselspital, Bern, Switzerland
[10] Gustave Roussy Canc Ctr DITEP, Villejuif, France
[11] UCL, London, England
[12] Emory Bone Marrow & Stem Cell Transplant Ctr, Winship Canc Inst, Atlanta, GA USA
[13] Hackensack Univ, Hackensack Meridian Hlth Sch Med, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA
[14] Mayo Clin, Phoenix, AZ USA
[15] Mem Sloan Kettering Canc Ctr, New York, NY USA
[16] Univ klinikum Carl Gustav Carus Dresden, Dresden, Germany
[17] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[18] Bristol Myers Squibb Co, Celgene, Boudry, Switzerland
[19] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7526
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy results from TRANSCEND NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory large B-cell lymphoma
    Abramson, J.
    Palomba, M. L.
    Gordon, L.
    Lunning, M.
    Wang, M.
    Arnason, J.
    Mehta, A.
    Purev, E.
    Maloney, D.
    Andreadis, C.
    Sehgal, A.
    Solomon, S.
    Ghosh, N.
    Albertson, T.
    Garcia, J.
    Kostic, A.
    Li, D.
    Kim, Y.
    Siddiqi, T.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 94 - 95
  • [22] Safety and Efficacy Results From Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (Liso-cel) In Relapsed/refractory Large B-Cell Lymphoma
    Abramson, Jeremy
    Palomba, M. Lia
    Gordon, Leo
    Lunning, Matthew
    Wang, Michael
    Arnason, Jon
    Mehta, Amitkumar
    Purev, Enkhtsetseg
    Maloney, David
    Andreadis, Charalambos
    Sehgal, Alison
    Solomon, Scott
    Ghosh, Nilanjan
    Albertson, Tina
    Garcia, Jacob
    Kostic, Ana
    Li, Daniel
    Kim, Yeonhee
    Siddiqi, Tanya
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 43 - 44
  • [23] TRANSFORM Study: improved Quality of Life (QOL) with Lisocabtagen maraleucel (Liso-Cel), a CD19-targeted chimeric Antigen Receptor (CAR) T-Cell Therapy, compared with Standard of Care (SOC) as Second-line Therapy (2L) in Patients (pt) with R/R large B-Cell Lymphoma (LBCL)
    Glass, B.
    Abramson, J. S.
    Johnston, P. B.
    Kamdar, M.
    Ibrahimi, S.
    Izutsu, K.
    Arnason, J.
    Mutsaers, P.
    Lunning, M.
    Braverman, J.
    Liu, F. F.
    Crotta, A.
    Montheard, S.
    Previtali, A.
    Guo, S.
    Shi, L.
    Solomon, S. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 255 - 256
  • [24] Outpatient treatment with lisocabtagene maraleucel (liso-cel) across a variety of clinical sites from three ongoing clinical studies in relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
    Bachier, Carlos R.
    Godwin, John E.
    Andreadis, Charalambos
    Palomba, Maria Lia
    Abramson, Jeremy S.
    Sehgal, Alison R.
    Hildebrandt, Gerhard
    Stevens, Don A.
    Hoda, Daanish
    Licitra, Edward J.
    Siddiqi, Tanya
    Farazi, Thalia Andrea
    Kostic, Ana
    Trede, Nikolaus S.
    Wang, Lei
    Lymp, James
    Maloney, David G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion
    Siddiqi, Tanya
    Jaeger, Ulrich
    Moshkovich, Olga
    Braverman, Julia
    Liu, Fei Fei
    Lanar, Sally
    Miera, Matthew
    Shah, Selam
    Devlen, Jennifer
    Salles, Gilles
    BLOOD, 2021, 138
  • [26] Lisocabtagene maraleucel (liso-cel) as second-line (2L) treatment (tx) for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Patient-reported outcomes (PRO) from the phase 2 PILOT study.
    Gordon, Leo I.
    Hoda, Daanish
    Shi, Ling
    Guo, Shien
    Liu, Fei Fei
    Braverman, Julia
    Dubowy, Ronald L.
    Peng, Lily
    Sehgal, Alison
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study
    Gordon, Leo I.
    Liu, Fei Fei
    Braverman, Julia
    Hoda, Daanish
    Ghosh, Nilanjan
    Hamadani, Mehdi
    Hildebrandt, Gerhard C.
    Peng, Lily
    Guo, Shien
    Shi, Ling
    Sehgal, Alison
    HAEMATOLOGICA, 2024, 109 (03) : 857 - 866
  • [28] Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy
    Siddiqi, Tanya
    Jaeger, Ulrich
    Moshkovich, Olga
    Devlen, Jennifer
    Miera, Matthew
    Williams, Agnes
    Hasskarl, Jens
    Liu, Fei Fei
    Braverman, Julia
    Salles, Gilles
    BLOOD, 2020, 136
  • [29] Matching-Adjusted Indirect Comparison (MAIC) of Axicabtagene Ciloleucel (Axi-Cel) and Lisocabtagene Maraleucel (Liso-Cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) After Two or More Prior Lines of Therapy
    Oluwole, Olalekan O.
    Chen, Jenny M. H.
    Chan, Keith
    Patel, Anik R.
    Jansen, Jeroen P.
    Keeping, Sam
    Bashir, Zahid
    Zheng, Yan
    Snider, Julia
    Locke, Frederick L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S388 - S388
  • [30] Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Linhares, Yuliya
    Freytes, Cesar
    Cherry, Mohamad
    Bachier, Carlos
    Maris, Michael
    Hoda, Daanish
    Varela, Juan Carlos
    Bellomo, Courtney
    Cross, Scott
    Essell, James
    Fanning, Suzanne
    Terebelo, Howard
    Yimer, Habte
    Courtright, Jay
    Sharman, Jeff P.
    Vedal, Min
    Mailley, Connor
    Espinola, Ricardo
    Mattar, Bassam
    BLOOD, 2022, 140 : 10416 - 10418
12345